Allogene Extends Cash Runway to 2029: What it Means for Biotech ETFs

Allogene Therapeutics has issued a strategic update regarding its capital reserves, projecting a cash runway that now extends into the first quarter of 2029. This announcement comes alongside a revision of its 2026 operating cash expense guidance, which has been raised to approximately $165 million. For market participants tracking the biotechnology sector through exchange-traded funds (ETFs) such as the XBI or IBB, this update provides a rare window into the long-term…